Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

West Nile virus: Therapeutic vaccines

04.11.2008
Researchers are developing a DNA-based vaccine against the dreaded West Nile virus (WNV), which can be transmitted from animals to humans. The unique feature of this vaccine is that it is also effective after onset of the disease, for it has therapeutic properties.

SARS, avian flu, Ebola – outbreaks of deadly viral infections are becoming increasingly frequent. And we still don’t have vaccines for many of the pathogens responsible. One of the most dangerous classes of viral diseases is the zoonosis, which can be transmitted from animals to humans with sometimes fatal consequences.

One of these is caused by the West Nile virus (WNV), which was first identified in Uganda in 1937. The virus was carried to the United States in 1999 and had spread through the whole of North America within five years. There is now a risk that it will propagate worldwide. Since its first appearance in the United States, around 400 people have died there after coming into contact with the West Nile virus. A new vaccine promises to provide protection.

Scientists at the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig have developed the DNA vaccine. “In this type of vaccine, DNA molecules known as plasmids extracted from the pathogen are used for inoculation, instead of the whole virus. They contain the genetic code for the antigens that stimulate the body to produce antibodies. We can thus replicate the virus’s natural infection route without actually triggering the disease,” explains Dr. Matthias Giese, the IZI’s head of vaccine development. Conventional methods of vaccination involve injecting a dead or weakened form of the pathogen into the patient’s body, which responds by producing the corresponding antibodies and developing immunity to the disease. An alternative is to inject a serum that already contains these antibodies. Such vaccines are merely preventive. By contrast with live vaccines, which carry a risk of provoking the disease, DNA vaccines are absolutely biologically safe. Moreover, they activate all existing defense mechanisms in the body, are cheap to produce and can be stored without a refrigerator – which makes them ideal for use in subtropical and tropical climates.

“Since the human immune system is very similar to that of other mammals, we are developing a cross-species vaccine for use in both veterinary and human medicine. And unlike conventional vaccines, DNA vaccines can be used both as prophylactics and as therapeutics, i.e. in cases where the disease is already present,” says Dr. Matthias Giese, citing the further benefits. The WNV vaccine has already passed initial tests. Giese expects the laboratory research to be completed by the end of 2009. After that, another 3 years or so will be needed for the approval procedure including clinical trials. Then, it is hoped, the world’s first therapeutic WNV vaccine will be ready for market.

Dr. Matthias Giese | alfa
Further information:
http://www.izi.frauhofer.de
http://www.fraunhofer.de/EN/press/pi/2008/11/ResearchNews112008Topic3.jsp

Further reports about: Cell Therapy DNA DNA-based vaccine Ebola NILE SARS Therapeutic vaccines Virus WNV West Nile virus avian flu zoonosis

More articles from Life Sciences:

nachricht Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory

nachricht How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>